Nammi Therapeutics Doses First Patient in QXL138AM Phase 1 Study
08 Nov 2024 //
PR NEWSWIRE
Amgen & Biolabs Announce Nammi To Receive The Third Amgen Golden Ticket
06 Jan 2023 //
PRESS RELEASE
Nammi Therapeutics Granted FDA ODD For QXL138AM for Multiple Myeloma
13 Jun 2022 //
PRNEWSWIRE

Market Place
Sourcing Support